Keyphrases
Diabetes Analysis
100%
A1 Receptor
100%
Glucagon-like
100%
Receptor Agonist
100%
Basal Insulin
100%
Type 2 Diabetic Patients
100%
Randomized Trial
100%
Adrenal Lymphoma
100%
HbA1c Levels
100%
D-excess
40%
Hemoglobin A1c (HbA1c)
36%
Hypoglycemia
27%
Insulin Therapy
18%
Treatment Difference
18%
Detemir
18%
Insulin Dose
18%
Onycholysis
16%
Related Quality of Life
9%
Liraglutide
9%
Open-label Trial
9%
Insulin
9%
Health Perception
9%
Hypoglycemia Risk
9%
Noninferiority Margin
9%
75th Percentile
9%
Treatment Strategy
9%
Total Daily Dose
9%
Safer Alternatives
9%
Diabetes Duration
9%
Treatment Satisfaction
9%
Uncontrolled Type 2 Diabetes
9%
Aspartate
9%
Diabetes
9%
Changes in Body Weight
9%
Hispanic
9%
Glycemic Control
9%
Effective Alternative
9%
Quality of Life Improvement
9%
Body Mass Index
9%
African American
9%
Nursing and Health Professions
Clinical Outcome
100%
Non Insulin Dependent Diabetes Mellitus
100%
Medication Compliance
100%
Hemoglobin A1c
100%
Liraglutide
75%
Quality of Life
75%
Hypoglycemia
75%
Metformin
25%
Titrimetry
25%
Patient-Reported Outcome
25%
Drug Therapy
25%
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
100%
Hypercalcaemia
80%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
80%
Adrenal Insufficiency
60%
Non-Hodgkin Lymphoma
40%
Cyclophosphamide
20%
Constipation
20%
Symptom
20%
Rituximab
20%
Doxorubicin
20%
Corticosteroid
20%
Hormone Substitution
20%
Nausea
20%
Rare Disease
20%
Hydrocortisone
20%
Brain Metastasis
20%
Prednisone
20%
Vincristine
20%
Hypotension
20%
Onycholysis
16%